Strategies to manage hepatitis C virus infection disease burden—Volume 4

The hepatitis C virus (HCV) epidemic was forecasted through 2030 for 17 countries in Africa, Asia, Europe, Latin America and the Middle East, and interventions for achieving the Global Health Sector Strategy on viral hepatitis targets—“WHO Targets” (65% reduction in HCV‐related deaths, 90% reduction in new infections and 90% of infections diagnosed by 2030) were considered. Scaling up treatment and diagnosis rates over time would be required to achieve these targets in all but one country, even with the introduction of high SVR therapies. The scenarios developed to achieve the WHO Targets in all countries studied assumed the implementation of national policies to prevent new infections and to diagnose current infections through screening.

T. F. Rinke de Wit | V. Wong | C. Hu | O. Tsang | B. Uzochukwu | L. Roberts | T. Su | M. Yuen | H. Razavi | H. Chan | S. Tsang | R. Mohamed | J. Layden | P. Chen | D. S. Chen | R. Chien | R. Phillips | R. Njouom | O. Opare-Sem | S. Owusu‐Ofori | A. Vince | S. Al-Busafi | H. Al-Romaihi | Z. Ghandour | W. Chuang | A. Nersesov | C. Loo | P. Ondoa | A. Bane | I. Kotzev | K. Tchernev | J. Al Salman | Said A. Al-Busafi | W. Ampofo | C. Estes | I. Gamkrelidze | E. Ngige | S. Sanad | F. Arome | J. Khamis | J. Al Qamish | A. Lo | W. Lao | K. Razavi-Shearer | J. Fung | R. Jahis | M. Morović | Y. Kamel | S. Oguche | I. Hrstic | Manik Sharma | J. Kao | S. Blach | D. Jelev | O. Akin | J. Genov | O. Lesi | D. Nonković | B. Lukšić | S. Robbins | W. Hamoudi | O. Njoya | C. Tzeuton | S. Himatt | M. Derbala | C. Rios | C. Anyaike | M. Youbi | Y. Hui | K. Al Naamani | A. Maaroufi | D. Adda | B. Gómez | J. Schmelzer | K. Yesmembetov | R. Mitova | M. Lai | A. Workneh | M. Simonova | A. Malu | C. J. Chen | D. Razavi-Shearer | S. A. Al Kaabi | A. John | N. Al Dweik | K. Al Ejji | K. Sultan | M. T. Butt | S. S. Tan | K. Kaliaskarova | M. H. Lee | V. Garcia | T. Reic | B. Mustapha | L. Mateva | M. Abdelmageed | M. Abdulla | A. Al Baqali | I. Al Ghazzawi | M. Al Sadadi | M. Albadri | K. Antonov | M. M. Borodo | S. Brandon | B. Bright | I. Cardenas | D. Cuellar | A. A. Elbardiny | E. Farag | M. Ghuloom | J. Gunter | J. Habeeb | O. Hajelssedig | C. Huang | H. Khattabi | I. Khoudri | A. Konysbekova | M. Li | K. Murphy | H. Nde | D. Nonković | S. Obekpa | E. Okolo | O. Omede | C. Omuemu | Y. Prokopenko | B. Redae | S. Ugoeze | R. Vi | H. Wani | R. Yacoub | C. C. Hu | S. Tan | S. Owusu-Ofori | M. Borodo | C. Ríos | S. J. Sanad | V. García | D. Razavi‐Shearer | M. AlBadri | P. Chen | D. Chen

[1]  T. F. Rinke de Wit,et al.  Historical epidemiology of hepatitis C virus in select countries—volume 4 , 2017, Journal of viral hepatitis.

[2]  T. F. Rinke de Wit,et al.  The present and future disease burden of hepatitis C virus infections with today's treatment paradigm: Volume 4 , 2017, Journal of viral hepatitis.

[3]  Gamal Esmat,et al.  Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. , 2017, The lancet. Gastroenterology & hepatology.

[4]  Chien-Jen Chen,et al.  Chronic hepatitis C virus infection and the risk for diabetes: a community‐based prospective study , 2017, Liver international : official journal of the International Association for the Study of the Liver.

[5]  E. Yoshida,et al.  Concordance of sustained virologic response at weeks 4, 12 and 24 post-treatment of hepatitis c in the era of new oral direct-acting antivirals: A concise review. , 2016, Annals of hepatology.

[6]  O. Weiland,et al.  A risk for hepatocellular carcinoma persists long-term after sustained virologic response in patients with hepatitis C-associated liver cirrhosis. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  J. Ward The hidden epidemic of hepatitis C virus infection in the United States: occult transmission and burden of disease. , 2013, Topics in antiviral medicine.

[8]  Rebecca L Morgan,et al.  Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. , 2012, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[9]  Derek B Boothroyd,et al.  Predictors of response of US veterans to treatment for the hepatitis C virus. , 2007, Hepatology.